Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety, tolerability, pharmacokinetics, and efficacy of TRTL-913 in healthy adults and adults with tinnitus. The study has two parts Part A is a double-blind phase assessing 7 days of dosing in healthy volunteers to understand how the drug behaves in the body and its safety profile. Part B is an open-label phase evaluating a 2-week treatment course in adults with tinnitus to assess safety and potential benefits. Participants in Part A will be randomly assigned to receive either TRTL-913 capsules or a matching placebo once daily for 7 days. In Part B, participants with tinnitus will self-administer TRTL-913 capsules once daily for 14 days, with dosing possibly adjusted based on Part A results. The study uses a parallel design and includes careful monitoring throughout both parts. During the study, participants will undergo safety assessments including vital signs, laboratory tests, ECGs, and monitoring for adverse events. For Part B, researchers will measure changes in tinnitus severity using standard tools like the Tinnitus Functional Index and Tinnitus Handicap Inventory over 21 days. The study will also assess plasma concentrations of TRTL-913 in Part A. Participants are closely monitored for any signs of suicidal thoughts or behavior. The total study duration varies depending on the part but involves up to 21 days of observation.
Actively Recruiting
Psoriatic arthritis PsA is a chronic inflammatory condition affecting the joints and skin of people with psoriasis PsO. This research aims to evaluate how well the drug zasocitinib works in adults with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The study is a phase 3 trial comparing zasocitinib to an active comparator and placebo to assess treatment effects and safety. Participants are randomly assigned to one of four groups. One group receives zasocitinib Dose A orally once daily for up to 52 weeks, another group receives zasocitinib Dose B once daily for the same period, a third group receives the active comparator capsules twice daily for up to 52 weeks, and the fourth group receives placebo once daily for 16 weeks followed by zasocitinib Dose A or B from Week 16 to Week 52. This design allows comparison between different doses, placebo, and active treatments. During the study, participants will be monitored regularly with evaluations including joint assessments and skin lesion checks. Researchers will measure responses such as improvement in arthritis symptoms using the American College of Rheumatology 20 ACR20 response at Week 16 as the primary outcome. Secondary measures include skin improvement and various quality of life and disease activity scores. The study duration for participants is up to 60 weeks, including treatment and follow-up, to assess both efficacy and safety of the treatments.
Actively Recruiting
Psoriatic arthritis PsA is a chronic inflammatory condition affecting joints and skin. This Phase 3 study aims to assess the long-term safety, tolerability, and effectiveness of the drug zasocitinib in adults with active PsA. It includes adults who have completed a previous year-long treatment in related parent studies and evaluates continued treatment over an extended period. Participants who previously took zasocitinib will maintain their assigned dose, while those initially on a different treatment will be randomly assigned to one of two doses of zasocitinib, taken once daily as oral tablets. The study treatment phase lasts up to 104 weeks, followed by a 4-week health monitoring period, totaling about 2 years of participation. During the study, participants will be regularly monitored for side effects, vital signs, and lab tests to assess safety. Researchers will also evaluate treatment effectiveness using criteria like the American College of Rheumatology response and skin improvement scores at multiple time points. After treatment, a follow-up period will ensure participants health is observed for any ongoing effects.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety, how the body processes, and the effects of a new drug called TRB-061, given as injections under the skin, in healthy adults and people with moderate-to-severe atopic dermatitis AD. This Phase 1a1b study includes healthy volunteers and patients to explore different dosing schedules and amounts in a randomized, double-blind, placebo-controlled setting. The study has three parts Part 1 involves healthy adults receiving a single dose of TRB-061 or placebo Part 2 includes healthy adults receiving three doses every 4 weeks over 8 weeks and Part 3 involves participants with moderate-to-severe AD receiving four doses every 4 weeks over 12 weeks. In Part 3, participants may also opt to switch treatments after the first period. Placebo doses match the appearance and schedule of TRB-061. Participants will attend multiple visits for dosing and follow-up, including safety checks, blood tests to measure drug levels, and assessments of side effects up to 12 weeks after dosing in Part 1, 10 weeks after dosing in Part 2, and through the end of the study in Part 3. Researchers will track adverse events, drug levels in the blood, and responses to treatment during the study, which runs until early 2028.
Actively Recruiting
Researchers are evaluating the clinical efficacy and safety of OD-07656 in adults with moderately to severely active ulcerative colitis UC. The study also aims to assess whether OD-07656 can improve the benefits of vedolizumab when given after OD-07656 treatment. This Phase 2a study is sponsored by Odyssey Therapeutics and focuses on patients who have had an inadequate response or intolerance to various UC therapies. Participants will receive oral doses of OD-07656 twice daily in one of three dosing regimens, with some groups randomized to different doses. Following the OD-07656 treatment phase, subsequent vedolizumab therapy will be evaluated for its therapeutic effects. The study design includes an open-label part and a randomized part, each assessing treatment safety and efficacy over specified periods. During the study, participants will be monitored through regular assessments including the 3-component Modified Mayo Clinic Score at baseline and after 12 weeks of OD-07656 treatment. Researchers will track treatment-emergent adverse events and treatment discontinuations. Clinical remission rates will be evaluated both after OD-07656 treatment and following vedolizumab therapy up to 50 weeks. The total participation period and detailed monitoring schedules will be managed according to the study protocol.